Home > Insider Trading > Filing (0001179110-13-000744)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012140	Onyx Pharmaceuticals Inc	ONXX	Biological Products, (No Disgnostic Substances) (2836)	943154463

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1225509	M Suzanne Shema	C/O Onyx Pharmaceuticals, Inc. 249 E. Grand Ave. South San Francisco CA 94080	Evp, Gc And Corp. Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-01-07	1,344	$32.07	35,177	No	4	M	Direct
Common Stock	Acquisiton	2013-01-07	656	$30.28	35,833	No	4	M	Direct
Common Stock	Acquisiton	2013-01-07	802	$35.18	36,635	No	4	M	Direct
Common Stock	Acquisiton	2013-01-07	1,050	$37.68	37,685	No	4	M	Direct
Common Stock	Acquisiton	2013-01-07	2,388	$37.68	40,073	No	4	M	Direct
Common Stock	Disposition	2013-01-07	4,740	$81.12	35,333	No	4	S	Direct
Common Stock	Disposition	2013-01-07	1,500	$81.99	33,833	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2013-01-07	1,344	$0.00	1,344	$32.07
Common Stock	Stock Option (Right to Buy)	Disposition	2013-01-07	656	$0.00	656	$30.28
Common Stock	Stock Option (Right to Buy)	Disposition	2013-01-07	802	$0.00	802	$35.18
Common Stock	Stock Option (Right to Buy)	Disposition	2013-01-07	1,050	$0.00	1,050	$37.68
Common Stock	Stock Option (Right to Buy)	Disposition	2013-01-07	2,388	$0.00	2,388	$37.68

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,187	2019-08-31	No	4	M	Direct
9,844	2020-03-31	No	4	M	Direct
21,657	2021-03-31	No	4	M	Direct
22,750	2022-03-29	No	4	M	Direct
31,037	2022-03-29	No	4	M	Direct

Footnotes

Shares sold pursuant to a 10b5-1 plan.
25% of the shares subject to the option become exercisable one year following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 36 months for a total vesting schedule of 48 months.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
The shares vest monthly from the date of grant at a rate of 1/48th per month.
The shares were sold at prices ranging from $80.09 to $81.4801. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices ranging from $81.93 to $82.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.